Uncoupling protein-2 mRNA expression in mice subjected to intermittent hypoxia^*

Abstracts

Objective:

To investigate the effect of intermittent hypoxia-a model of obstructive sleep apnea (OSA)-on pancreatic expression of uncoupling protein-2 (UCP2), as well as on glycemic and lipid profiles, in C57BL mice.

Methods:

For 8 h/day over a 35-day period, male C57BL mice were exposed to intermittent hypoxia (hypoxia group) or to a sham procedure (normoxia group). The intermittent hypoxia condition involved exposing mice to an atmosphere of 92% N and 8% CO₂ for 30 s, progressively reducing the fraction of inspired oxygen to 8 ± 1%, after which they were exposed to room air for 30 s and the cycle was repeated (480 cycles over the 8-h experimental period). Pancreases were dissected to isolate the islets. Real-time PCR was performed with TaqMan assays.

Results:

Expression of UCP2 mRNA in pancreatic islets was 20% higher in the normoxia group than in the hypoxia group (p = 0.11). Fasting serum insulin was higher in the hypoxia group than in the normoxia group (p = 0.01). The homeostasis model assessment of insulin resistance indicated that, in comparison with the control mice, the mice exposed to intermittent hypoxia showed 15% lower insulin resistance (p = 0.09) and 21% higher pancreatic β-cell function (p = 0.01). Immunohistochemical staining of the islets showed no significant differences between the two groups in terms of the area or intensity of α- and β-cell staining for insulin and glucagon.

Conclusions:

To our knowledge, this is the first report of the effect of intermittent hypoxia on UCP2 expression. Our findings suggest that UCP2 regulates insulin production in OSA. Further study of the role that UCP2 plays in the glycemic control of OSA patients is warranted.

Blood glucose; Sleep apnea syndromes; Pancreas; Glucagon-secreting cells

Objetivo:

Investigar o efeito da hipóxia intermitente com um modelo de apneia obstrutiva do sono (AOS) sobre a expressão de uncoupling protein-2 (UCP2), assim como sobre perfis glicêmicos e lipídicos, em camundongos C57BL.

Métodos:

Camundongos C57BL machos foram expostos a hipóxia intermitente ou hipóxia simulada (grupo controle) 8 h/dia durante 35 dias. A condição de hipóxia intermitente envolveu a exposição dos camundongos a uma atmosfera de 92% de N e 8% de CO₂ por 30 s, com redução progressiva de fração de O₂ inspirado até 8 ± 1%, seguida por exposição a ar ambiente por 30 s e repetições do ciclo (480 ciclos no período experimental de 8 h). Os pâncreas foram dissecados para isolar as ilhotas. Foi realizada PCR em tempo real utilizando o método TaqMan.

Resultados:

A expressão do mRNA da UCP2 nas ilhotas pancreáticas foi 20% maior no grupo controle que no grupo hipóxia (p = 0,11). A insulina sérica de jejum foi maior no grupo hipóxia do que no grupo controle (p = 0,01). O modelo de avaliação da homeostase de resistência à insulina indicou que, em comparação com os camundongos controle, aqueles expostos à hipóxia intermitente apresentaram 15% menor resistência à insulina (p = 0,09) e 21% maior função das células beta (p = 0,01). A coloração das ilhotas pancreáticas por imuno-histoquímica não mostrou diferenças significativas entre os grupos em termos da área ou da intensidade das células alfa e beta, marcadas por insulina e glucagon.

Conclusões:

Segundo nosso conhecimento, esta é a primeira descrição do efeito da hipóxia intermitente sobre a expressão da UCP2. Nossos achados sugerem que UCP2 regula a produção de insulina na AOS. Futuras investigações sobre o papel da UCP2 no controle glicêmico em pacientes com AOS são justificadas.

Glicemia; Síndromes da apneia do sono; Pâncreas; Células secretoras de glucagon

Introduction

Obstructive sleep apnea (OSA) is characterized by recurrent collapse of the pharynx during sleep. Each apneic event results in oxygen desaturation and, occasionally, arousal, causing intermittent hypoxia, oxidative stress, and sleep fragmentation. ^{( 1 )} Up to 32% of the adult population is affected by OSA.^{( 2 )}

Various cardiovascular and metabolic outcomes have been attributed to OSA.^{( 3 )} Metabolic syndrome shares several features with OSA, including obesity, hyperlipidemia, hypertension, and insulin resistance, which might be implicated in an increased risk of cardiovascular disease.^{( 4 - 6 )} In patients with OSA, metabolic syndrome can be improved by treatment with continuous positive airway pressure,^{( 7 - 9 )} indicating a causal relationship between the two conditions.

Experimental models that subject animals to intermittent hypoxia are used in order to study the consequences of OSA. Insulin resistance and metabolic changes have been reported after exposure to such models.^{( 10 , 11 )} The mechanisms underlying the changes in glucose metabolism induced by intermittent hypoxia have yet to be fully explored.

Uncoupling protein-2 (UCP2) is a negative regulator of pancreatic β-cell insulin secretion. ^{( 12 - 14 )} The UCPs, located in the mitochondrial inner membrane, translocate protons from the intermembrane space to the mitochondrial matrix. The protons that leak through a UCP can no longer be used to drive the rotation of ATP synthase, such proton leakage thus decreasing the generation of ATP. By abating ATP synthesis, UCP2 regulates glucose-stimulated insulin secretion.^{( 15 )} Free radicals generated during hypoxia-reoxygenation in sleep apnea may play a regulatory role in the pancreatic β-cells.^{( 16 )} This is the rationale for investigating a possible apnea-UCP2 relationship.

Because of the epidemic proportions that diabetes and OSA are assuming, there is interest in understanding the interplay between these two conditions. In an extensive search of the literature, we found no reference to the molecular regulation of insulin secretion in OSA. We hypothesized that intermittent hypoxia would change the expression of UCP2. Therefore, we investigated the effect of intermittent hypoxia on pancreatic UCP2 expression in C57BL mice.

Methods

Animals and intermittent hypoxia

We evaluated 36 male C57BL mice, in two groups: exposed to intermittent hypoxia (hypoxia group, n = 18); and subjected to a control (sham) procedure (normoxia group, n = 18). All of the mice were 8-9 weeks of age at the start of the study. All procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals,^{( 17 )} and the study protocol was approved by the Research Ethics Committee of the Porto Alegre Hospital de Clínicas, in the city of Porto Alegre, Brazil (Protocol no. 09-300).

Groups of 6 mice were housed under temperature-controlled conditions (22.5-24.5ºC), on a 12/12-h light/dark cycle (lights on at 7:00 a.m.), and provided with standard mouse chow and water ad libitum. Using a precision balance with a resolution of 0.01 g (AS 5500C; Marte Científica, São Paulo, Brazil), we weighed the mice at baseline and every 3 days thereafter, until the end of the experiment. The food pellets in each cage were weighed daily, in order to quantify food intake.

Over a period of 35 days, for 8 h a day during the lights-on period (from 9:00 a.m. to 5:00 p.m.), the mice were placed in the intermittent hypoxia system. In the intermittent hypoxia condition, a gas mixture consisting of 92% nitrogen and 8% CO₂ was released into the hypoxia chamber for 30 s, progressively reducing the fraction of inspired oxygen (FiO₂) from 21% to a nadir of 8 ± 1%. Next, a fan moved room air into the chamber for 30 s, restoring the FiO₂ to 21% within 5 s. Therefore, each hypoxia/normoxia cycle lasted for 60 s (60 cycles/h), for a total of 480 hypoxia cycles over the 8-h period. In the control (normoxia) condition (sham procedure), the mice were housed in an adjacent cage and were exposed to the same fan-off/fan-on cycles, although no gas mixture was released into the chamber at any point.

At the end of the experimental period, the animals were fasted for 6-10 h, after which they were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). After anesthesia was confirmed, blood samples were collected from the retro-orbital sinus. The mice were exsanguinated during the procedure. Blood samples were centrifuged at 10,000 rpm for 10 min at 4ºC to obtain serum samples. The pancreases of 12 mice per group were dissected, extracted, soaked for 24 h in five volumes of tissue storage reagent (RNAlater^(r); Applied Biosystems/Ambion, Austin, TX, USA), and stored at 4ºC overnight, after which they were frozen at −80ºC until analysis. The pancreases of 6 mice per group were fixed in 10% formalin for 24 h and embedded in paraffin for future processing.

Real-time PCR for UCP2, islet immunohistochemistry, and biochemical assays

The pancreases were unfrozen, dissected to isolate the islets, and homogenized in optimized phenol/guanidine-based lysis solution. Total RNA was isolated using TRI reagent solution (Applied Biosystems/Ambion). We quantified RNA and tested its quality by photometric measurement on a spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE, USA). Using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), we synthesized cDNA from 2 µg of highly purified RNA (A260/A280>1.95). The cDNA was stored at −20ºC and diluted in DNase-free water (1:100) before relative quantification by real-time PCR. Gene expression analysis was performed using TaqMan Gene Expression Assays for the UCP2 gene (Mm00627598_m1; Applied Biosystems), using the following primer sequences: forward, 5′-ACAAGACCATTGCACGAGAG-3′ and reverse, 5′-ATGAGGTTGGCTTTCAGGAG-3′. The results were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Thermal cycling was performed in a real-time PCR system (StepOne(tm); Applied Biosystems).

Gene expression was quantified using the 2-ΔΔCt (threshold cycle) method.^{( 18 )} Each sample was analyzed in duplicate, and the ΔCt value was obtained by subtracting the GAPDH Ct value from the Ct value of the UCP2 gene. To calculate the difference between groups, the mean ΔCt value obtained for the control group was used to calculate the ΔΔCt of the gene (2-ΔΔCt).

The paraffin-embedded pancreases were sectioned into 5-µm slices. Sections were mounted on glass slides, coated with 3-aminopropyltriethoxysilane, deparaffinized with xylene (two changes, 5 min each), and rehydrated in a graded ethanol series (four successive washes), after which they were immersed in distilled water and PBS. For antigen retrieval, the slides were immersed in 10 mM sodium citrate buffer, pH 6.0, heated in a microwave oven for 21 min and cooled to room temperature. To inhibit endogenous peroxidase activity, the slides were twice immersed in 5% hydrogen peroxide for 15 min. Nonspecific antibody-binding sites were blocked with 5% nonfat dry milk diluted in PBS for 20 min. Immunohistochemistry staining for β- and α-cells was performed using polyclonal guinea pig anti-insulin (A0564, 1:200 dilution; Dako, Carpinteria, CA, USA) and rabbit polyclonal antibody to glucagon (GA 1181, 1:4,000; Enzo Life Sciences, Farmingdale, NY, USA), respectively. After three washes, in running water, distilled water, and PBS, respectively, the slides were incubated for 1 h in a humidity chamber at room temperature. They were then washed once with distilled water and three times with PBS, after which they were incubated with a secondary antibody (Picture-MAX Polymer Kit; Invitrogen, Camarillo, CA, USA) for 30 min in the humidity chamber. We developed the slides using 3,3'-diaminobenzidine as chromogen, according to manufacturer instructions. The slides were then counterstained with Harris's hematoxylin for 20 s, washed in running water, and rinsed with ammonium hydroxide to obtain a light blue color. They were subsequently washed once with water, twice with ethanol, and three times with xylene. All sections were analyzed under light microscopy (magnification, ×400), digitized, and assessed with a computer image analysis system (Image-Pro Plus, version 6.0; Media Cybernetics, Bethesda, MD, USA). The area of β-cells in the islets was determined by the insulin-positive cell area, which was calculated as the ratio of intra-islet insulin-positive area to total islet area. The relative area of glucagon, which represented the amount of α-cells in each islet, was evaluated by the same method. The insulin positive- and glucagon positive-cell indices for each group were calculated as the average of at least 24 sections. Nuclei were not taken into account for quantitative analysis of islet cell composition.

Fasting serum glucose, total cholesterol, HDL cholesterol, and triglycerides were measured by enzymatic colorimetric methods using commercially available kits (Labtest Diagnostics, Belo Horizonte, Brazil). We estimated LDL cholesterol levels by the Friedewald formula^{( 19 )}:

LDL cholesterol = (total cholesterol − HDL cholesterol − triglycerides) ∕ 5

Fasting serum insulin was determined using a mouse insulin ELISA kit (ALPCO Diagnostics, Salem, NH, USA). Fasting serum glucagon was quantified with a glucagon enzyme immunoassay (EIA) kit (Phoenix Pharmaceuticals, Burlingame, CA). To evaluate the degree of insulin resistance, we calculated the homeostasis model assessment of insulin resistance (HOMA-IR) value, using the following formula^{( 20 )}:

HOMA-IR = fasting serum insulin (µU/mL) × fasting blood glucose (mmol/L) ∕ 22.5

In addition, we calculated the HOMA of pancreatic β-cell function (HOMA-β), as follows:

HOMA-β = [fasting serum insulin level (µU/mL) × 20] ∕ [fasting blood glucose level (mmol/L) − 3.5]

Statistical analysis

Data were tabulated and expressed as medians and interquartile ranges and in box plots showing 10th, 25th, 50th, 75th, and 90th percentiles, as well as outliers. The Mann-Whitney U test was used for between-group comparison of median UCP2 mRNA, insulin/glucagon-positive cell area, and biochemical assay values. Body weight in each group was adjusted for food intake using the generalized estimating equations (GEE) method, followed by pairwise comparisons with sequential Bonferroni correction. All statistical analyses were performed with the Statistical Package for the Social Sciences, version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Statistical significance was assumed if the probability of alpha error was < 0.05.

Results

Data showing the expression of UCP2 in both groups are displayed in Figure 1A. The relative expression of UCP2 was 16% lower in the hypoxia group than in the normoxia group, (0.82 [0.71-0.94] vs. 0.98 [0.78-1.19]), although the difference between the two groups was not significant (p = 0.11).

Figure 1 -
Box plots of glucose metabolism variables showing 10th, 25th, 50th, 75th, and 90th percentiles; outliers (filled circles); and extreme outliers (asterisk). UCP2: uncoupling protein-2; HOMA-IR: homeostasis model assessment of insulin resistance; and HOMA-β; homeostasis model assessment of pancreatic β-cell function. Values of p were calculated by the Mann-Whitney U test.

Fasting serum glucose levels (Figure 1B) were 12% lower in the hypoxia group than in the normoxia group (144 [115-156] vs. 163 [133-184] mg/dL; p = 0.025). Fasting serum insulin levels (Figure 1C) were 5% higher in the hypoxia group as compared with the normoxia group (0.44 [0.42-0.46] vs. 0.42 [0.40-0.44] ng/mL; p = 0.01). Fasting serum glucagon levels (Figure 1D) were 37% lower in the hypoxia group than in the normoxia group (6.84 [3.64-9.90] vs. 10.87 [7.43-14.21] ng/mL; p = 0.023).

After exposure to intermittent hypoxia, the mean HOMA-IR value (Figure 1E) was 15% lower in the hypoxia group than in the normoxia group, although the difference was not significant (3.45 [3.00-4.17] vs. 4.06 [3.35-4.55]; p = 0.095). The mean HOMA-β value (Figure 1F) was 21% higher in the hypoxia group than in the normoxia group (46.6 [42-74] vs. 36.6 [29-52]; p = 0.014).

As shown in Figure 2, the relative area of insulin-positive cells in the hypoxia group was non-significantly higher than in the normoxia group: 0.62 [0.56-0.67] vs. 0.56 [0.51-0.59] respectively (p = 0.14). The area of glucagon-positive cells was 0.10 [0.06-0.15] in the hypoxia group and 0.09 [0.08-0.17] in the normoxia group (p = 0.67).

Figure 2 -
Immunohistochemical staining for insulin and glucagon (magnification, ×400) with box plots of the relative area of the islet occupied by β-cells and α-cells. Box plots show 10th, 25th, 50th, 75th, and 90th percentiles; outliers (filled circles); and extreme outliers (asterisk).

Lipid profile parameters were compared between groups. Mice exposed to intermittent hypoxia did not differ significantly from the control mice in terms of fasting serum triglycerides or the levels of HDL, LDL, and total cholesterol.

Body weights remained relatively stable over the 35-day study period: 23.7 ± 0.3 g at day 1 versus 25.1 ± 0.3 g at day 35 in the normoxia group; and 24.6 ± 0.5 g at day 1 versus 24.8 ± 0.3 g at day 35 in the hypoxia group. Body weight entered as a dependent variable in the GEE model showed no effect of group allocation or of food intake. Time had a significant effect, and there was a significant interaction between time and group (p < 0.001 for both).

Discussion

To our knowledge, this was the first study to analyze the effect of an intermittent hypoxia-based model of OSA on the expression of UCP2 mRNA in the pancreas. In this model, exposure to 480 cycles per day of intermittent hypoxia with an 8% FiO₂ nadir for 35 days resulted in levels of UCP2 mRNA expression lower than those observed for the control condition, although the difference was not statistically significant. These preliminary results supplement the current knowledge of the mechanisms underlying the metabolic consequences of OSA, generating various hypotheses. The lack of a significant reduction in UCP2 expression in the hypoxia group might indicate that intermittent hypoxia has no effect on the expression of UCP2 or that it downregulates that expression to a degree below the threshold of the statistical power conveyed by the small number of animals evaluated.

The results of the present study add to the debate on the metabolic changes induced by OSA. Our data show that mice exposed to intermittent hypoxia had lower fasting serum glucose and glucagon levels than did the control mice. Previous studies have demonstrated that mice exposed to intermittent hypoxia show glucose levels that are either elevated^{( 10 , 21 )} or lowered. ^{( 11 )} Our findings agree with those of the latter study, which involved lean and obese C57BL/6J mice exposed to chronic intermittent hypoxia for 5 days.^{( 11 )} In the lean mice, glucose levels and insulin resistance decreased after hypoxia. In the obese (leptin-deficient) mice, glucose levels also decreased, although insulin resistance increased.^{( 11 )} In the present study, only lean mice were employed, and our results might therefore represent a true response of lean mice exposed to intermittent hypoxia as evidenced by the increased insulin levels and decreased levels of glucagon.

Our finding that fasting serum insulin levels and β-cell function were higher in the hypoxia group than in the normoxia group is consistent with the lower glucose and glucagon levels previously reported as a response to hypoxia. In previous studies, obese mice exposed to intermittent hypoxia showed higher insulin levels than did control mice,^{( 11 , 21 , 22 )} although the FiO₂ and exposure period differed from those employed in the present study. Another study showed that insulin levels were lower in lean mice exposed to intermittent hypoxia than in control mice.^{( 23 )}

In the present study, insulin levels were higher in mice exposed to intermittent hypoxia than in the control mice. The significantly lower levels of glucagon found in the hypoxia group might indicate that compensatory mechanisms are activated to maintain glucose homeostasis. A review of the literature found no comparable studies reporting the response of glucagon to intermittent hypoxia.

No differences in insulin resistance were detected by HOMA-IR in the mice subjected to intermittent hypoxia, their glucose levels being lower than were those of controls. The HOMA-β value was higher in the former group, suggesting that some mechanism-perhaps a lowering of UCP2 levels-was activated in order to increase insulin production. The HOMA-IR and HOMA-β have not been validated for use in rodents, the formula for the latter representing a measure of β-cell function in humans.^{( 24 )} However, the difference in the insulin to glucose ratio suggests that the mice might become insulin resistant, as previously reported.^{( 11 )}

To date, there have been few reports in the literature addressing pancreatic β-cell function and sleep. In the experiment reported here, the HOMA-β values were significantly elevated in the animals exposed to intermittent hypoxia for 35 days, being 10% higher in the hypoxia group than in the normoxia group. The increase in the HOMA-β value implies that OSA causes an excessive increase in the functional demand on pancreatic β-cells, which leads to worsening of insulin secretion as the disease progresses.

Our findings should be interpreted with caution. The data related to glucose levels might be unreliable, because even the normoxia group mice had high glucose levels, despite fasting. One possible explanation for this, other than an error in measurement, is that, although the food pellets were removed from the cages, a significant ration could have remained inside the cage. However, the error might have been systematic, the lower glucose level in the hypoxia group being an effect of the higher insulin level. Although the result is negative, further exploration of the effect of intermittent hypoxia on UCP2 could be useful. Models employing UCP2 knockout mice could clarify the actual reaction of this protein to intermittent hypoxia. An oral glucose challenge would confirm insulin resistance, and a curve would be more informative than are single measurements. Although difficult in mice, this has been done previously.^{( 6 )} The low triglycerides suggest that the hypoxia group mice were not eating as much as were the normoxia group mice. This could be a potential confounder of the findings.

Hyperlipidemia is common in persons with sleep apnea. Experiments evaluating the effect of intermittent hypoxia on lipid profile have reported discordant findings due to inconsistency in methods among studies. Examples of parameters that vary from study to study and could account for discrepant findings are differences in the duration of exposure (in days and in hours per day), in the duration of each hypoxia cycle (in seconds), in the FiO₂ nadirs, and in mouse strains. The magnitude of the metabolic disorder induced by intermittent hypoxia depends on the nadir of FiO₂. Experiments using 10% FiO₂ as the nadir of the hypoxia cycle did not induce metabolic changes after 28 days. Conversely, using a 5% FiO₂ nadir led to changes in all lipid profile parameters.^{( 25 )} The moderate severity of intermittent hypoxia-both in terms of FiO₂ nadir and of hours of exposure per day-might be one reason for the absence of changes in lipid parameters in the present study. Similarly, the 8% FiO₂ nadir and 8 h of hours of exposure per day employed here might not have induced hypoxia severe enough to affect UCP2 expression.

In conclusion, our investigation of the effect of intermittent hypoxia on the expression of UCP2 mRNA in C57BL mice revealed that, after 35 days of exposure to intermittent hypoxia, there was no significant change in the expression of this regulatory protein. At the level of severity employed here, intermittent hypoxia causes changes in pancreatic function that might be unrelated to potential changes in the expression of UCP2 mRNA.

Acknowledgments

The authors would like to thank Professor Luise Meurer, MD, PhD, for her instrumental role in the immunohistochemistry analysis.

References

• ¹
  Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1): 47-112. http://dx.doi.org/10.1152/physrev.00043.2008
  » http://dx.doi.org/10.1152/physrev.00043.2008
• ²
  Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR. Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med. 2010;11(5):441-6. http://dx.doi.org/10.1016/j.sleep.2009.10.005
  » http://dx.doi.org/10.1016/j.sleep.2009.10.005
• ³
  Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62(7):569-76. http://dx.doi.org/10.1016/j.jacc.2013.05.045
  » http://dx.doi.org/10.1016/j.jacc.2013.05.045
• ⁴
  Trombetta IC, Somers VK, Maki-Nunes C, Drager LF, Toschi-Dias E, Alves MJ, et al. Consequences of comorbid sleep apnea in the metabolic syndrome - implications for cardiovascular risk. Sleep. 2010;33(9):1193-9.
• ⁵
  Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118(10):1080-1111. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.189375
  » http://dx.doi.org/10.1161/CIRCULATIONAHA.107.189375
• ⁶
  Yokoe T, Alonso LC, Romano LC, Rosa TC, O'Doherty RM, Garcia-Ocana A, et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. J Physiol. 2008;586(3):899-911. http://dx.doi.org/10.1113/jphysiol.2007.143586
  » http://dx.doi.org/10.1113/jphysiol.2007.143586
• ⁷
  Morgenstern M, Wang J, Beatty N, Batemarco T, Sica AL, Greenberg H. Obstructive sleep apnea: an unexpected cause of insulin resistance and diabetes. Endocrinol Metab Clin North Am. 2014;43(1):187-204. http://dx.doi.org/10.1016/j.ecl.2013.09.002
  » http://dx.doi.org/10.1016/j.ecl.2013.09.002
• ⁸
  Weinstock TG, Wang X, Rueschman M, Ismail-Beigi F, Aylor J, Babineau DC, et al. A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. Sleep. 2012;35(5):617-25B. http://dx.doi.org/10.5665/sleep.1816
  » http://dx.doi.org/10.5665/sleep.1816
• ⁹
  Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest. 2008;134(4):686-92. http://dx.doi.org/10.1378/chest.08-0556
  » http://dx.doi.org/10.1378/chest.08-0556
• ¹⁰
  Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med. 2007;175(8):851-7. http://dx.doi.org/10.1164/rccm.200610-1527OC
  » http://dx.doi.org/10.1164/rccm.200610-1527OC
• ¹¹
  Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol. 2003;552(Pt 1):253-64. http://dx.doi.org/10.1113/jphysiol.2003.048173
  » http://dx.doi.org/10.1113/jphysiol.2003.048173
• ¹²
  Liu J, Li J, Li WJ, Wang CM. The role of uncoupling proteins in diabetes mellitus. J Diabetes Res. 2013;2013:585897. http://dx.doi.org/10.1155/2013/585897
  » http://dx.doi.org/10.1155/2013/585897
• ¹³
  Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001;105(6):745-55. http://dx.doi.org/10.1016/S0092-8674(01)00378-6
  » http://dx.doi.org/10.1016/S0092-8674(01)00378-6
• ¹⁴
  Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001;50(6):1302-10. http://dx.doi.org/10.2337/diabetes.50.6.1302
  » http://dx.doi.org/10.2337/diabetes.50.6.1302
• ¹⁵
  Echtay KS. Mitochondrial uncoupling proteins--what is their physiological role? Free Radic Biol Med. 2007;43(10):1351-71. http://dx.doi.org/10.1016/j.freeradbiomed.2007.08.011
  » http://dx.doi.org/10.1016/j.freeradbiomed.2007.08.011
• ¹⁶
  Pi J, Collins S. Reactive oxygen species and uncoupling protein 2 in pancreatic ß-cell function. Diabetes Obes Metab. 2010; Suppl 2:141-8. http://dx.doi.org/10.1111/j.1463-1326.2010.01269.x
  » http://dx.doi.org/10.1111/j.1463-1326.2010.01269.x
• ¹⁷
  National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US), 2011.
• ¹⁸
  Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. http://dx.doi.org/10.1006/meth.2001.1262
  » http://dx.doi.org/10.1006/meth.2001.1262
• ¹⁹
  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
• ²⁰
  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. http://dx.doi.org/10.1007/BF00280883
  » http://dx.doi.org/10.1007/BF00280883
• ²¹
  Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol (1985). 2011;111(3):881-90. http://dx.doi.org/10.1152/japplphysiol.00492.2011
  » http://dx.doi.org/10.1152/japplphysiol.00492.2011
• ²²
  Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity (Silver Spring). 2011;19(11):2167-74. http://dx.doi.org/10.1038/oby.2011.240
  » http://dx.doi.org/10.1038/oby.2011.240
• ²³
  Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology. 2007;45(4):1007-13. http://dx.doi.org/10.1002/hep.21593
  » http://dx.doi.org/10.1002/hep.21593
• ²⁴
  Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. http://dx.doi.org/10.2337/diacare.27.6.1487
  » http://dx.doi.org/10.2337/diacare.27.6.1487
• ²⁵
  Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol (1985). 2007;102(2):557-63. http://dx.doi.org/10.1152/japplphysiol.01081.2006
  » http://dx.doi.org/10.1152/japplphysiol.01081.2006

• *
  Study carried out under the auspices of the Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
• Financial support: This study received financial support from the Fundo de Incentivo à Pesquisa do Hospital de Clínicas de Porto Alegre (FIPE-HCPA, Research Incentive Fund of the Porto Alegre Hospital de Clínicas) and from the Brazilian Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, National Council for Scientific and Technological Development; scholarship grant to CZ Fiori and research fellowship grant to D Martinez).

Publication Dates

• Publication in this collection
  18 Apr 2015
• Date of issue
  Mar-Apr 2015

History

• Received
  17 Sept 2014
• Accepted
  05 Dec 2014